Do analysts rate VRAX or BIVI?

Virax Biolabs Group presently has a consensus price target of $25.00, suggesting a potential upside of 683.70%. Given Virax Biolabs Group's stronger consensus rating and higher probable upside, equities analysts plainly believe Virax Biolabs Group is more favorable than BioVie. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Virax Biolabs Group 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 BioVie 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation and earnings, VRAX or BIVI?

Virax Biolabs Group has higher revenue and earnings than BioVie. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Virax Biolabs Group $12.42K 204.66 -$5.02M N/A N/A BioVie N/A N/A -$17.54M -$2.45 N/A

Is VRAX or BIVI more profitable?

Virax Biolabs Group's return on equity of 0.00% beat BioVie's return on equity. Company Net Margins Return on Equity Return on Assets Virax Biolabs Group N/A N/A N/A BioVie N/A -101.15% -90.18%

Does the media favor VRAX or BIVI?

In the previous week, Virax Biolabs Group had 1 more articles in the media than BioVie. MarketBeat recorded 3 mentions for Virax Biolabs Group and 2 mentions for BioVie. Virax Biolabs Group's average media sentiment score of 1.24 beat BioVie's score of 0.62 indicating that Virax Biolabs Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Virax Biolabs Group 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioVie 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, VRAX or CALC?

Virax Biolabs Group has higher revenue and earnings than CalciMedica. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Virax Biolabs Group $12.42K 204.66 -$5.02M N/A N/A CalciMedica N/A N/A -$29.56M -$1.31 N/A

Is VRAX or CALC more profitable?

Virax Biolabs Group's return on equity of 0.00% beat CalciMedica's return on equity. Company Net Margins Return on Equity Return on Assets Virax Biolabs Group N/A N/A N/A CalciMedica N/A -863.40% -144.33%

Do analysts rate VRAX or FNCH?

Virax Biolabs Group presently has a consensus target price of $25.00, indicating a potential upside of 683.70%. Given Virax Biolabs Group's stronger consensus rating and higher probable upside, research analysts clearly believe Virax Biolabs Group is more favorable than Finch Therapeutics Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Virax Biolabs Group 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Finch Therapeutics Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable earnings & valuation, VRAX or FNCH?

Virax Biolabs Group has higher revenue and earnings than Finch Therapeutics Group. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Virax Biolabs Group $12.42K 204.66 -$5.02M N/A N/A Finch Therapeutics Group N/A N/A -$74.75M -$8.82 N/A

Is VRAX or FNCH more profitable?

Virax Biolabs Group's return on equity of 0.00% beat Finch Therapeutics Group's return on equity. Company Net Margins Return on Equity Return on Assets Virax Biolabs Group N/A N/A N/A Finch Therapeutics Group N/A -69.14% -26.92%

Do analysts prefer VRAX or MYNZ?

Virax Biolabs Group presently has a consensus target price of $25.00, suggesting a potential upside of 683.70%. Given Virax Biolabs Group's stronger consensus rating and higher possible upside, analysts clearly believe Virax Biolabs Group is more favorable than Mainz Biomed. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Virax Biolabs Group 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Mainz Biomed 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has better earnings & valuation, VRAX or MYNZ?

Virax Biolabs Group has higher earnings, but lower revenue than Mainz Biomed. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Virax Biolabs Group $12.42K 204.66 -$5.02M N/A N/A Mainz Biomed $659.94K 14.83 -$21.65M -$65.60 N/A

Is VRAX or MYNZ more profitable?

Company Net Margins Return on Equity Return on Assets Virax Biolabs Group N/A N/A N/A Mainz Biomed N/A N/A N/A

Does the media favor VRAX or MYNZ?

In the previous week, Virax Biolabs Group had 2 more articles in the media than Mainz Biomed. MarketBeat recorded 3 mentions for Virax Biolabs Group and 1 mentions for Mainz Biomed. Virax Biolabs Group's average media sentiment score of 1.24 beat Mainz Biomed's score of 0.75 indicating that Virax Biolabs Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Virax Biolabs Group 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mainz Biomed 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, VRAX or CMMB?

Virax Biolabs Group has higher revenue and earnings than Chemomab Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Virax Biolabs Group $12.42K 204.66 -$5.02M N/A N/A Chemomab Therapeutics N/A N/A -$8.99M -$2.22 N/A

Is VRAX or CMMB more profitable?

Virax Biolabs Group's return on equity of 0.00% beat Chemomab Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Virax Biolabs Group N/A N/A N/A Chemomab Therapeutics N/A -89.03% -79.68%

Virax Biolabs Group (VRAX) Competitors

$3.19 0.00 (0.00%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$3.18 -0.02 (-0.47%)

As of 07/24/2026 07:34 PM Eastern

Compare

VRAX vs. BIVI, CALC, FNCH, MYNZ, and CMMB

Should you buy Virax Biolabs Group stock or one of its competitors? MarketBeat compares Virax Biolabs Group with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Virax Biolabs Group include BioVie (BIVI), CalciMedica (CALC), Finch Therapeutics Group (FNCH), Mainz Biomed (MYNZ), and Chemomab Therapeutics (CMMB). These companies are all part of the "pharmaceutical products" industry.

How does Virax Biolabs Group compare to BioVie?

Virax Biolabs Group (NASDAQ:VRAX) and BioVie (NASDAQ:BIVI) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, risk, institutional ownership and dividends.

8.6% of Virax Biolabs Group shares are owned by institutional investors. Comparatively, 4.6% of BioVie shares are owned by institutional investors. 45.1% of Virax Biolabs Group shares are owned by company insiders. Comparatively, 0.9% of BioVie shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Virax Biolabs Group's return on equity of 0.00% beat BioVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Virax Biolabs Group	N/A	N/A	N/A
BioVie	N/A	-101.15%	-90.18%

Virax Biolabs Group presently has a consensus price target of $25.00, suggesting a potential upside of 683.70%. Given Virax Biolabs Group's stronger consensus rating and higher probable upside, equities analysts plainly believe Virax Biolabs Group is more favorable than BioVie.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Virax Biolabs Group	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
BioVie	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Virax Biolabs Group has higher revenue and earnings than BioVie.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Virax Biolabs Group	$12.42K	204.66	-$5.02M	N/A	N/A
BioVie	N/A	N/A	-$17.54M	-$2.45	N/A

In the previous week, Virax Biolabs Group had 1 more articles in the media than BioVie. MarketBeat recorded 3 mentions for Virax Biolabs Group and 2 mentions for BioVie. Virax Biolabs Group's average media sentiment score of 1.24 beat BioVie's score of 0.62 indicating that Virax Biolabs Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Virax Biolabs Group	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioVie	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Virax Biolabs Group has a beta of 1.35, suggesting that its share price is 35% more volatile than the broader market. Comparatively, BioVie has a beta of 0.57, suggesting that its share price is 43% less volatile than the broader market.

Summary

Virax Biolabs Group beats BioVie on 12 of the 12 factors compared between the two stocks.

How does Virax Biolabs Group compare to CalciMedica?

Virax Biolabs Group (NASDAQ:VRAX) and CalciMedica (NASDAQ:CALC) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, risk, media sentiment and valuation.

Virax Biolabs Group has higher revenue and earnings than CalciMedica.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Virax Biolabs Group	$12.42K	204.66	-$5.02M	N/A	N/A
CalciMedica	N/A	N/A	-$29.56M	-$1.31	N/A

In the previous week, Virax Biolabs Group had 1 more articles in the media than CalciMedica. MarketBeat recorded 3 mentions for Virax Biolabs Group and 2 mentions for CalciMedica. CalciMedica's average media sentiment score of 1.44 beat Virax Biolabs Group's score of 1.24 indicating that CalciMedica is being referred to more favorably in the news media.

Company	Overall Sentiment
Virax Biolabs Group	Positive
CalciMedica	Positive

Virax Biolabs Group currently has a consensus price target of $25.00, indicating a potential upside of 683.70%. CalciMedica has a consensus price target of $10.00, indicating a potential upside of 1,215.96%. Given CalciMedica's higher possible upside, analysts plainly believe CalciMedica is more favorable than Virax Biolabs Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Virax Biolabs Group	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
CalciMedica	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Virax Biolabs Group's return on equity of 0.00% beat CalciMedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Virax Biolabs Group	N/A	N/A	N/A
CalciMedica	N/A	-863.40%	-144.33%

8.6% of Virax Biolabs Group shares are owned by institutional investors. 45.1% of Virax Biolabs Group shares are owned by company insiders. Comparatively, 41.5% of CalciMedica shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Virax Biolabs Group has a beta of 1.35, suggesting that its stock price is 35% more volatile than the broader market. Comparatively, CalciMedica has a beta of 0.89, suggesting that its stock price is 11% less volatile than the broader market.

Summary

Virax Biolabs Group beats CalciMedica on 8 of the 10 factors compared between the two stocks.

How does Virax Biolabs Group compare to Finch Therapeutics Group?

Virax Biolabs Group (NASDAQ:VRAX) and Finch Therapeutics Group (NASDAQ:FNCH) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, profitability, risk, earnings and dividends.

8.6% of Virax Biolabs Group shares are owned by institutional investors. Comparatively, 21.8% of Finch Therapeutics Group shares are owned by institutional investors. 45.1% of Virax Biolabs Group shares are owned by insiders. Comparatively, 44.9% of Finch Therapeutics Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Virax Biolabs Group has higher revenue and earnings than Finch Therapeutics Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Virax Biolabs Group	$12.42K	204.66	-$5.02M	N/A	N/A
Finch Therapeutics Group	N/A	N/A	-$74.75M	-$8.82	N/A

In the previous week, Virax Biolabs Group had 3 more articles in the media than Finch Therapeutics Group. MarketBeat recorded 3 mentions for Virax Biolabs Group and 0 mentions for Finch Therapeutics Group. Virax Biolabs Group's average media sentiment score of 1.24 beat Finch Therapeutics Group's score of 0.00 indicating that Virax Biolabs Group is being referred to more favorably in the media.

Company	Overall Sentiment
Virax Biolabs Group	Positive
Finch Therapeutics Group	Neutral

Virax Biolabs Group has a beta of 1.35, suggesting that its stock price is 35% more volatile than the broader market. Comparatively, Finch Therapeutics Group has a beta of 1.18, suggesting that its stock price is 18% more volatile than the broader market.

Virax Biolabs Group presently has a consensus target price of $25.00, indicating a potential upside of 683.70%. Given Virax Biolabs Group's stronger consensus rating and higher probable upside, research analysts clearly believe Virax Biolabs Group is more favorable than Finch Therapeutics Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Virax Biolabs Group	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Finch Therapeutics Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Virax Biolabs Group's return on equity of 0.00% beat Finch Therapeutics Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Virax Biolabs Group	N/A	N/A	N/A
Finch Therapeutics Group	N/A	-69.14%	-26.92%

Summary

Virax Biolabs Group beats Finch Therapeutics Group on 11 of the 12 factors compared between the two stocks.

How does Virax Biolabs Group compare to Mainz Biomed?

Virax Biolabs Group (NASDAQ:VRAX) and Mainz Biomed (NASDAQ:MYNZ) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, institutional ownership, valuation, dividends and profitability.

8.6% of Virax Biolabs Group shares are held by institutional investors. 45.1% of Virax Biolabs Group shares are held by insiders. Comparatively, 18.2% of Mainz Biomed shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Virax Biolabs Group had 2 more articles in the media than Mainz Biomed. MarketBeat recorded 3 mentions for Virax Biolabs Group and 1 mentions for Mainz Biomed. Virax Biolabs Group's average media sentiment score of 1.24 beat Mainz Biomed's score of 0.75 indicating that Virax Biolabs Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Virax Biolabs Group	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mainz Biomed	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Virax Biolabs Group has higher earnings, but lower revenue than Mainz Biomed.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Virax Biolabs Group	$12.42K	204.66	-$5.02M	N/A	N/A
Mainz Biomed	$659.94K	14.83	-$21.65M	-$65.60	N/A

Virax Biolabs Group presently has a consensus target price of $25.00, suggesting a potential upside of 683.70%. Given Virax Biolabs Group's stronger consensus rating and higher possible upside, analysts clearly believe Virax Biolabs Group is more favorable than Mainz Biomed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Virax Biolabs Group	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Mainz Biomed	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Virax Biolabs Group has a beta of 1.35, meaning that its stock price is 35% more volatile than the broader market. Comparatively, Mainz Biomed has a beta of 0.31, meaning that its stock price is 69% less volatile than the broader market.

Company	Net Margins	Return on Equity	Return on Assets
Virax Biolabs Group	N/A	N/A	N/A
Mainz Biomed	N/A	N/A	N/A

Summary

Virax Biolabs Group beats Mainz Biomed on 10 of the 11 factors compared between the two stocks.

How does Virax Biolabs Group compare to Chemomab Therapeutics?

Virax Biolabs Group (NASDAQ:VRAX) and Chemomab Therapeutics (NASDAQ:CMMB) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, media sentiment, valuation, profitability and risk.

8.6% of Virax Biolabs Group shares are held by institutional investors. Comparatively, 46.0% of Chemomab Therapeutics shares are held by institutional investors. 45.1% of Virax Biolabs Group shares are held by company insiders. Comparatively, 11.9% of Chemomab Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Virax Biolabs Group's return on equity of 0.00% beat Chemomab Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Virax Biolabs Group	N/A	N/A	N/A
Chemomab Therapeutics	N/A	-89.03%	-79.68%

Virax Biolabs Group currently has a consensus price target of $25.00, indicating a potential upside of 683.70%. Chemomab Therapeutics has a consensus price target of $25.00, indicating a potential upside of 1,738.24%. Given Chemomab Therapeutics' higher probable upside, analysts plainly believe Chemomab Therapeutics is more favorable than Virax Biolabs Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Virax Biolabs Group	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Chemomab Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Virax Biolabs Group had 2 more articles in the media than Chemomab Therapeutics. MarketBeat recorded 3 mentions for Virax Biolabs Group and 1 mentions for Chemomab Therapeutics. Chemomab Therapeutics' average media sentiment score of 1.89 beat Virax Biolabs Group's score of 1.24 indicating that Chemomab Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Virax Biolabs Group	Positive
Chemomab Therapeutics	Very Positive

Virax Biolabs Group has a beta of 1.35, meaning that its share price is 35% more volatile than the broader market. Comparatively, Chemomab Therapeutics has a beta of 0.64, meaning that its share price is 36% less volatile than the broader market.

Virax Biolabs Group has higher revenue and earnings than Chemomab Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Virax Biolabs Group	$12.42K	204.66	-$5.02M	N/A	N/A
Chemomab Therapeutics	N/A	N/A	-$8.99M	-$2.22	N/A

Summary

Virax Biolabs Group beats Chemomab Therapeutics on 7 of the 10 factors compared between the two stocks.

Get Virax Biolabs Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VRAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VRAX vs. The Competition

Export

Metric	Virax Biolabs Group	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.54M	$3.67B	$6.87B	$12.26B
Dividend Yield	N/A	2.19%	2.67%	9.79%
P/E Ratio	N/A	21.48	27.14	23.64
Price / Sales	204.66	170.08	517.08	89.45
Price / Cash	N/A	157.90	50.54	59.64
Price / Book	0.08	7.88	10.28	6.07
Net Income	-$5.02M	$23.86M	$3.60B	$331.99M
7 Day Performance	-15.83%	-3.82%	-1.27%	-0.63%
1 Month Performance	-5.48%	-2.61%	-0.37%	-2.00%
1 Year Performance	-87.10%	32.79%	18.30%	13.62%

Virax Biolabs Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VRAX Virax Biolabs Group	3.0583 of 5 stars	$3.19 flat	$25.00 +683.7%	-87.6%	$2.54M	$12.42K	N/A	5	Short Interest Decrease Gap Up
BIVI BioVie	0.3969 of 5 stars	$1.77 +12.0%	N/A	-81.9%	$11.92M	N/A	N/A	10
CALC CalciMedica	3.9179 of 5 stars	$0.78 +5.0%	$10.00 +1,179.6%	-79.4%	$11.76M	N/A	N/A	30	Positive News Short Interest Decrease Gap Up
FNCH Finch Therapeutics Group	N/A	$7.30 flat	N/A	N/A	$11.72M	N/A	N/A	190
MYNZ Mainz Biomed	0.4499 of 5 stars	$1.26 flat	N/A	-44.2%	$11.42M	$659.94K	N/A	30	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VRAX) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Virax Biolabs Group (VRAX) Competitors

VRAX vs. BIVI, CALC, FNCH, MYNZ, and CMMB

How does Virax Biolabs Group compare to BioVie?

Summary

How does Virax Biolabs Group compare to CalciMedica?

Summary

How does Virax Biolabs Group compare to Finch Therapeutics Group?

Summary

How does Virax Biolabs Group compare to Mainz Biomed?

Summary

How does Virax Biolabs Group compare to Chemomab Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRAX vs. The Competition

Virax Biolabs Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Virax Biolabs Group (VRAX) Competitors

VRAX vs. BIVI, CALC, FNCH, MYNZ, and CMMB

How does Virax Biolabs Group compare to BioVie?

Do institutionals and insiders have more ownership in VRAX or BIVI?

Is VRAX or BIVI more profitable?

Do analysts rate VRAX or BIVI?

Which has stronger valuation and earnings, VRAX or BIVI?

Does the media favor VRAX or BIVI?

Which has more volatility & risk, VRAX or BIVI?

Summary

How does Virax Biolabs Group compare to CalciMedica?

Which has higher valuation and earnings, VRAX or CALC?

Does the media favor VRAX or CALC?

Do analysts rate VRAX or CALC?

Is VRAX or CALC more profitable?

Do institutionals & insiders believe in VRAX or CALC?

Which has more volatility and risk, VRAX or CALC?

Summary

How does Virax Biolabs Group compare to Finch Therapeutics Group?

Do insiders & institutionals believe in VRAX or FNCH?

Which has preferable earnings & valuation, VRAX or FNCH?

Does the media favor VRAX or FNCH?

Which has more risk & volatility, VRAX or FNCH?

Do analysts rate VRAX or FNCH?

Is VRAX or FNCH more profitable?

Summary

How does Virax Biolabs Group compare to Mainz Biomed?

Do insiders & institutionals believe in VRAX or MYNZ?

Does the media favor VRAX or MYNZ?

Which has better earnings & valuation, VRAX or MYNZ?

Do analysts prefer VRAX or MYNZ?

Which has more volatility & risk, VRAX or MYNZ?

Is VRAX or MYNZ more profitable?

Summary

How does Virax Biolabs Group compare to Chemomab Therapeutics?

Do institutionals and insiders believe in VRAX or CMMB?

Is VRAX or CMMB more profitable?

Do analysts prefer VRAX or CMMB?

Does the media favor VRAX or CMMB?

Which has more risk and volatility, VRAX or CMMB?

Which has higher valuation & earnings, VRAX or CMMB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRAX vs. The Competition

Virax Biolabs Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools